Literature DB >> 27900105

Palliative sequential chemoradiotherapy for pulmonary sulcus tumor: A case report.

Miki Kikuchi1, Toshihiro Ohtani2, Tomohiro Tamura3, Hiroaki Satoh3.   

Abstract

Pulmonary sulcus tumors are occasionally encountered in non-small-cell lung cancer (NSCLC) patients. If the patients have a good clinical condition, concurrent chemoradiotherapy is indicated. However, palliative chemotherapy and chemoradiotherapy for patients exhibiting a poor overall condition have not been reported to date. We herein report the case of a 54-year-old female patient with a pulmonary sulcus tumor, who had a poor performance status. The patient received sequential chemoradiotherapy, with no severe complications. There was no local recurrence until the time of death, 8 months after the initiation of therapy. Palliative sequential chemoradiotherapy for pulmonary sulcus NSCLC must be effective and carry low risk of complications. Palliative sequential chemoradiotherapy may be considered in certain patients with pulmonary sulcus NSCLC. Either chemotherapy or radiotherapy is administered first and, if there is no apparent deterioration of the patient's general condition, the next treatment modality is administered.

Entities:  

Keywords:  pulmonary sulcus tumor; sequential chemoradiotherapy

Year:  2016        PMID: 27900105      PMCID: PMC5103892          DOI: 10.3892/mco.2016.1026

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  11 in total

Review 1.  Management and future directions in non-small cell lung cancer with known activating mutations.

Authors:  David E Gerber; Leena Gandhi; Daniel B Costa
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 2.  Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)?

Authors:  C Peedell; J Dunning; A Bapusamy
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-03-26       Impact factor: 4.126

Review 3.  Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.

Authors:  Aaron M Laine; Kenneth D Westover; Hak Choy
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

4.  Treatment of advanced non small cell lung cancer.

Authors:  Maria Anna Bareschino; Clorinda Schettino; Antonio Rossi; Paolo Maione; Paola Claudia Sacco; Rosario Zeppa; Cesare Gridelli
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

5.  Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.

Authors:  Virag K Dandekar; Jennifer Young; Krystyna Kiel; Philip Bonomi; Mary J Fidler; Marta Batus; David J Sher
Journal:  Am J Clin Oncol       Date:  2015-12       Impact factor: 2.339

Review 6.  Refining the treatment of NSCLC according to histological and molecular subtypes.

Authors:  Anish Thomas; Stephen V Liu; Deepa S Subramaniam; Giuseppe Giaccone
Journal:  Nat Rev Clin Oncol       Date:  2015-05-12       Impact factor: 66.675

Review 7.  Chemoradiotherapy for stage III non-small cell lung cancer: have we reached the limit?

Authors:  Peng Xu; Cecile Le Pechoux
Journal:  Chin Clin Oncol       Date:  2015-12

8.  Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy.

Authors:  Erkan Topkan; Berna Akkus Yildirim; Ozan Cem Guler; Cem Parlak; Berrin Pehlivan; Ugur Selek
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

Review 9.  First- and second-line therapy for advanced nonsmall cell lung cancer.

Authors:  J-P Sculier; D Moro-Sibilot
Journal:  Eur Respir J       Date:  2009-04       Impact factor: 16.671

Review 10.  Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.

Authors:  Delphine Antoni; Françoise Mornex
Journal:  Curr Opin Oncol       Date:  2016-03       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.